These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2186856)

  • 1. Modification of thrombogenic factors in cardiac disease.
    Genton E
    Cardiovasc Clin; 1990; 20(3):127-32. PubMed ID: 2186856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism.
    Chesebro JH; Fuster V
    Circulation; 1986 Nov; 74(5 Pt 2):III1-10. PubMed ID: 3533316
    [No Abstract]   [Full Text] [Related]  

  • 3. Coronary thrombolysis. Principles and practice.
    Erhardt L; Emanuelsson H; Hartford M; Johnsson H; Strandberg LE
    Acta Med Scand; 1988; 224(5):413-24. PubMed ID: 2974233
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention.
    Garg R; Uretsky BF; Lev EI
    Catheter Cardiovasc Interv; 2007 Sep; 70(3):388-406. PubMed ID: 17722043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antithrombotic strategies in cardiovascular diseases.
    Golino P; Loffredo F; Riegler L; Renzullo E; Cocchia R
    Curr Opin Investig Drugs; 2005 Mar; 6(3):298-306. PubMed ID: 15816507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging antithrombotic treatments for acute coronary syndromes.
    Golino P; Ragni M; Cirillo P; Buono C; Piro O; Chiariello M
    Cardiologia; 1999 Nov; 44(11):969-80. PubMed ID: 10686772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of thrombosis: physiopathology, role of thrombin and its inhibition by modern therapies].
    Hamon M
    Arch Mal Coeur Vaiss; 2006 Feb; 99 Spec no.3():5-9. PubMed ID: 16553237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Following coronary thrombolysis.
    Sherry S
    Adv Exp Med Biol; 1987; 214():255-63. PubMed ID: 3310544
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of experimental coronary thrombosis by hirudin.
    Bucha E; Nowak G; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):52-8. PubMed ID: 2459032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of magnesium as antithrombotic therapy.
    Shechter M
    Wien Med Wochenschr; 2000; 150(15-16):343-7. PubMed ID: 11105330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
    Fitchett D; Goodman SG; Gupta M; Langer A
    Can J Cardiol; 2002 Nov; 18(11):1179-90. PubMed ID: 12464982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-implant antithrombotic treatment after intracoronary stents. Thrombotic occlusion].
    Alonso Martín JJ; Durán Hernández JM; Gimeno de Carlos F; de la Fuente Galán L; Muñoz San José JC; Fernández-Avilés F
    Rev Esp Cardiol; 1997; 50 Suppl 2():31-43. PubMed ID: 9221455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update in cardiology.
    Sanz J; Fuster V
    Ann Intern Med; 2010 Jun; 152(12):786-91. PubMed ID: 20410449
    [No Abstract]   [Full Text] [Related]  

  • 14. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current trends in antithrombotic drug and device development.
    Fareed J
    Semin Thromb Hemost; 1996; 22 Suppl 1():3-8. PubMed ID: 8807721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing subacute stent thrombosis--is there a role for heparin-coated stents?
    Carrozza JP
    J Invasive Cardiol; 2003 Aug; 15(8):442-3. PubMed ID: 12890873
    [No Abstract]   [Full Text] [Related]  

  • 17. [Persistent activation and/or reactivation in the subacute phase of unstable angina. Reasons for prolonged antithrombotic treatment].
    Lidón RM
    Rev Esp Cardiol; 1999; 52 Suppl 1():90-6. PubMed ID: 10364818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Patient at risk of endocoronary stent thrombosis during perioperative period: a frequent situation].
    Lehot JJ; Piriou V; Durand de Gevigney G; Coriat P
    Ann Fr Anesth Reanim; 2005 Oct; 24(10):1247-9. PubMed ID: 16099127
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
    Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
    Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.
    Becker RC
    Arch Pathol Lab Med; 1993 Jan; 117(1):89-96. PubMed ID: 8418769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.